
Erasca and Bristol Myers Squibb partner to test ERAS-0015 with navlimetostat in pancreatic cancer trial
Erasca, Inc. has entered a clinical collaboration with Bristol Myers Squibb to evaluate the combination of Erasca's ERAS-0015, a pan-RAS molecular glue, with BMS's investigational PRMT5 inhibitor navlimetostat in a Phase 1/2 trial targeting MTAP-dele...

